Show simple item record

dc.contributor.authorAppukuttan, Binoy
dc.contributor.authorMcFarland, Trevor J
dc.contributor.authorStempel, Andrew
dc.contributor.authorKassem, Jean B
dc.contributor.authorHartzell, Matthew
dc.contributor.authorZhang, Yi
dc.contributor.authorBond, Derek
dc.contributor.authorWest, Kelsey
dc.contributor.authorWilson, Reid
dc.contributor.authorStout, Andrew
dc.contributor.authorPan, Yuzhen
dc.contributor.authorIlias, Hoda
dc.contributor.authorRobertson, Kathryn
dc.contributor.authorKlein, Michael L
dc.contributor.authorWilson, David
dc.contributor.authorSmith, Justine R
dc.contributor.authorStout, J Timothy
dc.date.accessioned2013-01-30T04:14:33Z
dc.date.available2013-01-30T04:14:33Z
dc.date.issued2012-06-22
dc.identifier.citationAppukuttan, B., McFarland, T.J., Stempel, A., Kassem, J.B., Hartzell, M., Zhang, Y., Bond, D., West, K., Wilson, R., Stout, A., Pan, Y., Ilias, H., Robertson, K., Klein, M. L., Wilson, D., Smith, J.R. and Stout, J.T., 2012. The related transcriptional enhancer factor-1 isoform, TEAD4 216, can repress vascular endothelial growth factor expression in mammalian cells. PLoS One, 7(6), e31260.en
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/2328/26592
dc.description.abstractIncreased cellular production of vascular endothelial growth factor (VEGF) is responsible for the development and progression of multiple cancers and other neovascular conditions, and therapies targeting post-translational VEGF products are used in the treatment of these diseases. Development of methods to control and modify the transcription of the VEGF gene is an alternative approach that may have therapeutic potential. We have previously shown that isoforms of the transcriptional enhancer factor 1-related (TEAD4) protein can enhance the production of VEGF. In this study we describe a new TEAD4 isoform, TEAD4 216, which represses VEGF promoter activity. The TEAD4 216 isoform inhibits human VEGF promoter activity and does not require the presence of the hypoxia responsive element (HRE), which is the sequence critical to hypoxia inducible factor (HIF)-mediated effects. The TEAD4 216 protein is localized to the cytoplasm, whereas the enhancer isoforms are found within the nucleus. The TEAD4 216 isoform can competitively repress the stimulatory activity of the TEAD4 434 and TEAD4 148 enhancers. Synthesis of the native VEGF 165 protein and cellular proliferation is suppressed by the TEAD4 216 isoform. Mutational analysis indicates that nuclear or cytoplasmic localization of any isoform determines whether it acts as an enhancer or repressor, respectively. The TEAD4 216 isoform appears to inhibit VEGF production independently of the HRE required activity by HIF, suggesting that this alternatively spliced isoform of TEAD4 may provide a novel approach to treat VEGF-dependent diseases.en
dc.language.isoen
dc.publisherPublic Library of Scienceen
dc.subjectOphthalmologyen
dc.subjectCancer treatmenten
dc.titleThe related transcriptional enhancer factor-1 isoform, TEAD4 216, can repress vascular endothelial growth factor expression in mammalian cellsen
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record